Amylyx Pharmaceuticals, Inc. (AMLX) stock
Close on Nov 12, 2026Market cap $3.33BP/E –Yield –
Amylyx Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$123.48M. At the latest close the market valued the company at $3.33B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $3.33B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.41
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$163.20M
- EPS, diluted
- -$1.44
- Free cash flow
- -$123.48M
- Book value per share
- $6.34
- Diluted shares
- 119M
Trading
- Next earnings
- Mar 2, 2027 (estimated, before the open)
- Previous close
- $31.80
- Open
- $31.43
- Day's range
- $29.79 – $31.57
- Volume
- 1,473,328
- Average volume (20 days)
- 1,395,550
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.06
- 52-week range
- $10.83 – $41.14
- RSI (14 days)
- 62.7
- Volatility (1 year)
- 86.7%
- Relative volume
- 0.98×
- WACC
- 10.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMLX | S&P 500 | Difference | AMLX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.7% | -2.7% | +11.4 pts | ||
| 3 months | +27.9% | -1.7% | +29.6 pts | ||
| Year to date | +147.2% | +11.9% | +135.3 pts | ||
| 1 year | +142.2% | +12.0% | +130.2 pts | ||
| 3 years | +139.3% | +78.2% | +61.1 pts | +33.7% | +21.2% |
| 5 years | +210.7% | +73.2% | +137.5 pts | +25.5% | +11.6% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Amylyx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Update
About Amylyx Pharmaceuticals
Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for endocrine disorders and neurodegenerative diseases. Its pipeline includes avexitide, an investigational glucagon-like peptide-1 receptor antagonist undergoing evaluation for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for metabolic and rare conditions. Because its drug candidates remain in clinical and preclinical development, the company currently serves patient populations and study participants affected by these underserved medical conditions rather than commercial consumers.
Company profile, executives and historyAmylyx Pharmaceuticals stock: common questions
What is Amylyx Pharmaceuticals's stock price?
AMLX closed at $29.86 on Nov 12, 2026, down 6.10% on the day. Over the past 52 weeks it traded between $10.83 and $41.14.
What is Amylyx Pharmaceuticals's market cap?
Amylyx Pharmaceuticals was worth $3.33B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AMLX's P/E ratio?
Amylyx Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.44), so it has no meaningful P/E ratio.
How much revenue does Amylyx Pharmaceuticals make?
Amylyx Pharmaceuticals reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Amylyx Pharmaceuticals pay a dividend?
No. Amylyx Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Amylyx Pharmaceuticals report earnings next?
Amylyx Pharmaceuticals is expected to report Q4 FY2026 results on Mar 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AMLX stock performed over the past year?
Including dividends, AMLX returned +142.2% over the past year, against +12.0% for the S&P 500.
How many AMLX shares are sold short?
13M shares were sold short at the latest FINRA report, 12.51% of the float, or 10.5 days of average trading volume.
Who are Amylyx Pharmaceuticals's competitors?
Companies most similar to Amylyx Pharmaceuticals by business, industry and size include WVE, BCYC, PRTA, VTVT, SEPN.
See a number that looks wrong?